NYSE:ABBV Stock Report
Market Cap $369.16B
$208.71
+0.14%
+$0.29 today
Market Cap
$369.16B
P/E Ratio
Discount20.87
Sector: 27.23
EPS
$2.71
Volume
2.0M
Year High
$244.81
Year Low
$168.54
50-Day MA
Below$219.61
200-Day MA
Below$217.11
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. (ABBV) currently trades around $210.32 with a strong analyst consensus rating of Buy and a median price target of $258, indicating approximately 22% upside potential. The stock has demonstrated resilience and momentum, supported by a diversified portfolio and ongoing innovation. Recent analyst actions have largely maintained positive ratings, with only a minor downgrade from Wolfe Research, reflecting stable investor confidence. Key developments include promising Phase 2 clinical trial results for mirvetuximab soravtansine-gynx in platinum-sensitive ovarian cancer, which could expand AbbVie's oncology footprint. The neuroscience segment, driven by Botox and Vraylar, is expected to grow significantly, offsetting declines in legacy products. Additionally, the exclusive licensing agreement with Haisco Pharmaceutical Group to develop novel pain medicines enhances AbbVie's pipeline and global market presence. AbbVie's growth outlook is supported by a strong immunology portfolio with products like Skyrizi and Rinvoq surpassing previous benchmarks, and a robust pipeline of approximately 90 active clinical programs. Financially, the company maintains high operating margins and strong cash flow, positioning it well to invest in innovation and absorb pressures from legacy product declines. However, risks remain from regulatory uncertainties, pricing pressures, and competitive dynamics, particularly in oncology and immunology sectors. Looking forward, AbbVie is well-positioned to capitalize on near-term catalysts such as regulatory approvals for new formulations and pipeline advancements, while managing risks through strategic partnerships and operational efficiencies. Investors should monitor upcoming earnings releases and regulatory developments as key indicators of sustained momentum.
Price Target
40 analysts$255.92
Range: $223.00
→
$299.00
Upside Potential
+22.6%
From current price
Consensus Rating
Rating Distribution
Buy
Hold
Sell
AbbVie's positive growth trajectory is underpinned by several key catalysts across its portfolio and pipeline. The company recently reported encouraging Phase 2 data for mirvetuximab soravtansine-gynx in platinum-sensitive ovarian cancer, demonstrating a high objective response rate and manageable safety profile, which could translate into a valuable new oncology treatment. The neuroscience franchise, particularly Botox and Vraylar, is expected to grow by 22% in Q1, providing important top-line support amid challenges in older treatments. Strategic partnerships, such as the exclusive licensing agreement with Haisco Pharmaceutical Group for novel pain medicines, expand AbbVie's innovation pipeline and global reach, particularly outside China. Additionally, AbbVie's immunology portfolio remains a strong growth engine, with products like Skyrizi and Rinvoq surpassing peak sales of Humira and supporting projected revenue growth of approximately 9.5% in 2026. The company’s extensive pipeline of around 90 active clinical programs, including promising candidates in dermatology, obesity, and psychedelic antidepressants, offers a long runway for sustained growth. Financially, AbbVie benefits from high operating margins and robust cash flow generation, enabling continued investment in R&D and strategic acquisitions. Industry trends favor AbbVie’s focus on innovative immunology and dermatology treatments, supported by strong brand recognition and pricing power. These factors collectively create a compelling upside case for the stock, supported by a broad base of analyst buy ratings and significant price target upside.
AbbVie faces several notable risks that could impact its growth and valuation. Regulatory challenges are prominent, including ongoing litigation related to Washington State's 340B transparency law, which introduces uncertainty and potential financial liabilities. The oncology segment is under pressure from pricing challenges and competition, with legacy products like Imbruvica experiencing sales declines. The immunology market is increasingly competitive, with new oral therapies from rivals such as Johnson & Johnson and Bristol Myers Squibb threatening AbbVie's injectable treatment dominance. Industry-wide risks include potential regulatory changes affecting drug pricing and reimbursement policies, which could constrain revenue growth. Technological disruptions and market saturation in key therapeutic areas may limit AbbVie's ability to sustain high growth rates. Macro risks such as global economic volatility, trade tensions, and currency fluctuations also pose challenges to international operations and supply chains. Valuation concerns have surfaced as some analysts have downgraded the stock or lowered price targets, citing elevated expectations for AbbVie's immunology assets and the need for clearer pipeline execution visibility. Recent downward revisions to Q1 and full-year 2026 EPS guidance have tempered near-term sentiment. Additionally, potential policy risks like tariffs on imported branded drugs add further uncertainty. Investors should weigh these risks carefully against the company’s strong fundamentals and growth prospects.
Explore similar companies in the Healthcare sector